Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects.

Trial Profile

Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs BLI 489 (Primary)
  • Indications Bacterial infections; Urinary tract infections
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Oct 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Status changed from not yet recruiting to recriuting as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Location (USA) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top